Please login to the form below

Not currently logged in
Email:
Password:

presbyopia

This page shows the latest presbyopia news and features for those working in and with pharma, biotech and healthcare.

Novartis buys two firms in pre-Christmas shopping spree

Novartis buys two firms in pre-Christmas shopping spree

The takeover of Encore gives Novartis rights to EV06 (lipoic acid choline ester), a disease-modifying treatment for age-related loss of near distance vision (presbyopia) that can be delivered in ... Presbyopia affects 80% of people aged over 45 and makes

Latest news

  • FDA approves wireless contact lens sensor FDA approves wireless contact lens sensor

    In eye care Novartis has licensed the rights to Google's smart lens technology and is developing it for use in diabetes and presbyopia, with clinical trials due to begin later

  • You're in good hands You're in good hands

    Are we throwing expensive presbyopia-correcting intraocular lenses for cataract patients into this basket of goods?

  • Novartis buys rights to Google's 'smart lens' technology Novartis buys rights to Google's 'smart lens' technology

    Pharma company's eye unit Alcon will focus on uses in diabetes and presbyopia.  . ... The other is to help people with presbyopia – age-related long-sightedness that makes it more difficult to focus on objects that are near.  .

More from news
Approximately 2 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
infill healthcare communication

infill is a dynamic and innovative, international healthcare agency with >25 years' experience in delivering healthcare communication, medical education and...

Latest intelligence

China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...

Infographics